enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.760
+0.120 (7.32%)
At close: May 26, 2026, 4:00 PM EDT
1.660
-0.100 (-5.68%)
After-hours: May 26, 2026, 4:02 PM EDT
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,493,146
Market Cap
119.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| Alps Group | 93 |
| Verrica Pharmaceuticals | 76 |
| Rani Therapeutics Holdings | 71 |
| PepGen | 56 |
| Vivani Medical | 42 |
| Cognition Therapeutics | 14 |
ENGN News
- 12 days ago - enGene price target lowered to $2 from $9 at UBS - TheFly
- 17 days ago - enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain - MarketBeat
- 18 days ago - Leerink downgraded enGene to Market Perform following LEGEND update - TheFly
- 18 days ago - enGene downgraded to Perform from Outperform at Oppenheimer - TheFly
- 18 days ago - enGene downgraded to Market Perform from Outperform at Leerink - TheFly
- 18 days ago - enGene Therapeutics Proxy statement: Proxy filing - Filings
- 18 days ago - enGene downgraded to Outperform from Strong Buy at Raymond James - TheFly
- 18 days ago - enGene downgraded to Neutral from Buy at Guggenheim - TheFly